Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2019

20.09.2019 | short review

CML at the 2018 ASH meeting—selected presentations

verfasst von: Dr. Stefan Schmidt

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Summary

Treatment recommendations in chronic myeloid leukemia (CML) treatment have not changed substantially since treatment-free remission (TFR) has become a therapeutic option. Hence, allowing more patients to enter TFR is gaining significance. Although, Asciminib as a first-in-class new type of tyrosine kinase inhibitor (TKI) is in clinical development, currently combination treatment with TKIs and Interferon-alpha2b appears the best option to deepen molecular response and broaden the basis of potential TFR candidates. Improving the chances of a first successful TFR has to be the primary goal in TFR optimization as even re-induction of a deep molecular response after TFR failure using second generation TKIs shows disillusioning results.
Literatur
1.
Zurück zum Zitat Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20. CrossRefPubMed Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20. CrossRefPubMed
2.
Zurück zum Zitat Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51. CrossRefPubMedPubMedCentral Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. CrossRefPubMedPubMedCentral Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM‑L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7. CrossRefPubMed Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM‑L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7. CrossRefPubMed
7.
Zurück zum Zitat Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of Imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398. CrossRefPubMedPubMedCentral Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of Imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gambacorti-Passerini C, Antolini L, Mahon F‑X, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with Imatinib. J Natl Cancer Inst. 2011;103(7):553–61. CrossRefPubMed Gambacorti-Passerini C, Antolini L, Mahon F‑X, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with Imatinib. J Natl Cancer Inst. 2011;103(7):553–61. CrossRefPubMed
9.
Zurück zum Zitat Bettiol A, Marconi E, Lombardi N, Crescioli G, Gherlinzoni F, Walley T, et al. Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic myeloid leukemia. Clin Drug Investig. 2018;38(9):837–44. CrossRefPubMed Bettiol A, Marconi E, Lombardi N, Crescioli G, Gherlinzoni F, Walley T, et al. Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic myeloid leukemia. Clin Drug Investig. 2018;38(9):837–44. CrossRefPubMed
10.
Zurück zum Zitat Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of Imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22. CrossRefPubMed Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of Imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22. CrossRefPubMed
11.
Zurück zum Zitat Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30. CrossRefPubMed Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30. CrossRefPubMed
12.
Zurück zum Zitat Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57. CrossRefPubMed Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57. CrossRefPubMed
14.
Zurück zum Zitat Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, et al. Second attempt to discontinue Imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120(9):1959–60. CrossRefPubMedPubMedCentral Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, et al. Second attempt to discontinue Imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120(9):1959–60. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kim DDH, Busque L, Forrest DL, Savoie L, Bence-Bruckler I, Couban S, et al. Second attempt of TKI discontinuation with dasatinib for treatment-free remission after failing first attempt with Imatinib: treatment-free remission accomplished by dasatinib (TRAD) trial. Blood. 2018;132(Suppl 1):787. CrossRef Kim DDH, Busque L, Forrest DL, Savoie L, Bence-Bruckler I, Couban S, et al. Second attempt of TKI discontinuation with dasatinib for treatment-free remission after failing first attempt with Imatinib: treatment-free remission accomplished by dasatinib (TRAD) trial. Blood. 2018;132(Suppl 1):787. CrossRef
16.
Zurück zum Zitat Yeung DT, Grigg AP, Shanmuganathan N, Cunningham I, Shortt J, Rowling P, et al. Combination of nilotinib and pegylated interferon alfa-2b results in high molecular response rates in chronic phase CML: interim results of the ALLG CML 11 pinnacle study. Blood. 2018;132(Suppl 1):459. CrossRef Yeung DT, Grigg AP, Shanmuganathan N, Cunningham I, Shortt J, Rowling P, et al. Combination of nilotinib and pegylated interferon alfa-2b results in high molecular response rates in chronic phase CML: interim results of the ALLG CML 11 pinnacle study. Blood. 2018;132(Suppl 1):459. CrossRef
17.
Zurück zum Zitat Hochhaus A, Saussele S, Baerlocher GM, Brümmendorf TH, Burchert A, La Rosée P, et al. Nilotinib vs nilotinib plus pegylated interferon-alpha2b induction and nilotinib or pegylated interferon-alpha2b maintenance therapy for newly diagnosed BCR-ABL+ chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V)-study. Blood. 2018;132(Suppl 1):460. CrossRef Hochhaus A, Saussele S, Baerlocher GM, Brümmendorf TH, Burchert A, La Rosée P, et al. Nilotinib vs nilotinib plus pegylated interferon-alpha2b induction and nilotinib or pegylated interferon-alpha2b maintenance therapy for newly diagnosed BCR-ABL+ chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V)-study. Blood. 2018;132(Suppl 1):460. CrossRef
18.
Zurück zum Zitat Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525. CrossRefPubMedPubMedCentral Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525. CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Roy L, Chomel J‑C, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Combination of dasatinib and peg-interferon Alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French intergroup of CML (Fi-LMC). Blood. 2015;126(23):134. CrossRef Roy L, Chomel J‑C, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Combination of dasatinib and peg-interferon Alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French intergroup of CML (Fi-LMC). Blood. 2015;126(23):134. CrossRef
20.
Zurück zum Zitat Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5‑year study results of DASISION: the dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. CrossRefPubMedPubMedCentral Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5‑year study results of DASISION: the dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Hoglund M, Dreimane A, et al. Safety and efficacy of the combination of pegylated Interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30(9):1853–60. CrossRefPubMed Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Hoglund M, Dreimane A, et al. Safety and efficacy of the combination of pegylated Interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30(9):1853–60. CrossRefPubMed
22.
Zurück zum Zitat Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus pegInterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–21. CrossRefPubMed Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus pegInterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–21. CrossRefPubMed
23.
Zurück zum Zitat Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627–40. CrossRefPubMed Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627–40. CrossRefPubMed
24.
Zurück zum Zitat Rea D, Lang F, Kim D‑W, Cortes JE, Hughes TP, Minami H, et al. Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial. Blood. 2018;132(Suppl 1):792. CrossRef Rea D, Lang F, Kim D‑W, Cortes JE, Hughes TP, Minami H, et al. Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial. Blood. 2018;132(Suppl 1):792. CrossRef
Metadaten
Titel
CML at the 2018 ASH meeting—selected presentations
verfasst von
Dr. Stefan Schmidt
Publikationsdatum
20.09.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00529-4

Weitere Artikel der Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019 Zur Ausgabe